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Neutrophil-generated Free Radicals:
Possible Mechanisms of Injury in Adult
Respiratory Distress Syndrome
Joe M. McCord, Bifeng Gao, Jonathan Leff, and Sonia C. Flores
Webb-Waring Institute for Biomedical Research, University of Colorado Health Sciences Center, Denver,
Colorado
The acute lung injury resulting from adult respiratory distress syndrome (ARDS) is thought to be largely mediated by activated neutrophils. Because
activated neutrophils produce the superoxide radical, which is both bactericidal and cytotoxic to host cells, this oxygen-derived free radical is likely
responsible for at least part of the neutrophil-mediated lung injury. In a rat model of ARDS resulting from intratracheal instillation of interleukin-1,
recombinant human manganous superoxide dismutase significantly decreased lung leak. One detrimental action of proteases released by adherent
neutrophils may be the degradation of extracellular superoxide dismutase (ECSOD), which normally binds to the heparan sulfate on the surface of
the endothelium. We found that rabbit ECSOD incubated with either trypsin or activated neutrophils loses affinity for heparin. Furthermore, soluble
ECSOD is elevated in the serum of patients with ARDS, consistent with this hypothesis. - Environ Health Perspect 102(Suppl 10):57-60 (1994)
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Introduction
Adult respiratory distress syndrome
(ARDS) is a common and frequently lethal
complication of a number of conditions,
especially sepsis and trauma. The mortality
remains at around 50%, resulting from
leakage of fluid into the pulmonary inter-
stitium and alveoli (1). Considerable evi-
dence implicates the neutrophil as a
primary source of injury to the lungs (2).
In addition, there are numerous indica-
tions that patients with ARDS are in
oxidative stress, including elevated levels of
hydrogen peroxide in their expired breath
(3), oxidatively inactivated antiprotease in
their blood and lavage fluid (4), lipid per-
oxidation products in their blood (5), and
decreased levels of reduced glutathione in
blood and alveolar lining fluids (6).
In many laboratory models and in a
few clinical trials, superoxide dismutase
(SOD) has proven therapeutically useful in
protecting injured tissues from superoxide
radical, whether generated intracellularly or
by infiltrating activated neutrophils (7). Its
ability to protect tissues against any partic-
ular insult (ischemia, inflammation, hyper-
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oxia, etc.) depends on several parameters,
such as the rate ofplasma clearance (8), the
ability to equilibrate between extracellular
fluid compartments (9), and the ability to
closely approach negatively charged cell sur-
faces byvirtue ofits own net charge (10).
In humans, three types of SOD have
been extensively characterized: the cytoso-
lic Cu,Zn-SOD, a 32-kDa dimer (11), the
mitochondrial Mn-SOD, an 89-kDa
tetramer (12), and an extracellular SOD
(ECSOD) (13). This ECSOD (a 135,000-
mw tetrameric glycoprotein) is also a
cuprozinc enzyme. ECSOD is genetically
related to the smaller cytosolic enzyme,
and is found in a number oftissues but at a
much lower concentration than either of
the other two enzymes (14,15). However,
the major SOD in extracellular fluids is the
ECSOD. It is found as three post transla-
tionally generated isozymes: ECSOD-A
with no heparin affinity; ECSOD-B with
low heparin affinity; and ECSOD-C with
high heparin affinity, causing it to be
largely bound to heparan sulfate on
endothelial surfaces. The affinity for
polyanions is due to a highly hydrophilic,
positively charged carboxy-terminal "tail"
on each subunit of ECSOD-C (the native
form) (16).
Most studies published to date showing
the ability ofSOD to protect injured tissues
have employed the cytosolic Cu,Zn-SOD
(bovine, yeast, or human). This molecule
has the advantage of being commercially
available and relatively inexpensive, coupled
with the enormous disadvantage of having
very undesirable pharmacologic properties.
Its half-life in the plasma following iv
injection is from 6 to 15 min, depending
on species. Its net charge at physiologic pH
is negative, like that ofcell surfaces; hence,
it is repelled from those surfaces. Recently,
the human ECSOD has become available
in sufficient quantity to compare its
pharmacologic properties with those ofthe
other SODs, and it appears that ECSOD
may have a substantial advantage over
cytosolic Cu,Zn-SOD because ofits ability
to bind to the endothelium (17,18).
The contribution made by ECSOD to
the protection of the endothelium during
pathologic conditions, and especially when
the endothelium may be covered with
adherent, activated neutrophils, is largely
unexplored. Activated neutrophils release a
variety of proteolytic activities. The likeli-
hood that the hydrophilic tail of ECSOD,
rich in arginine and lysine, would be a tar-
get for these proteases prompted us to
examine the role ofECSOD in ARDS, and




Trypsin (Type III, bovine pancreas) was
from Sigma Chemical Co. (St. Louis,
MO). Human recombinant Cu,Zn- and
Mn-SODs were generously provided by
Biotechnology General, Inc. (New York,
NY). SOD was assayed by the method of
McCord and Fridovich (11) modified as
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necessary for increased sensitivity (19).
Rabbit ECSOD-C was purified by admin-
istering a lethal dose ofsodium pentobarbi-
tal (60 mg/kg) to a rabbit also injected iv
with 200 U heparin/kg bw. The rabbit was
exsanguinated and the blood centrifuged to
remove the cells. The plasma was fraction-
ated by heparin affinity chromatography as
described below. After elution by the
sodium chloride gradient, the peak frac-
tions were dialyzed against HBSS and con-
centrated by ultrafiltration (Amicon,
PM-10 membrane).
HeparinAffinityChromatography
A sample of SOD (500-2000 U) was
applied to a small (2-3 ml bed volume)
column of heparin-agarose (Sigma) in 10
mM Tris-Cl buffer, pH 7.4. The column
was washed with this buffer to remove
unbound enzyme, then eluted with a gradi-
ent of NaCl, 0 to 2.0 M. Fractions were
assayed for SOD activity and for conduc-
tivity. Native Cu,Zn- or Mn-SODs
showed no affinity for this column; rabbit
ECSOD-C was retained by the column,
eluting at 0.4 M NaCl.
Neutrophil IsolationandActivation
Human peripheral neutrophils were isolated
from freshly drawn blood obtained from
healthy donors as previously described (20)
and resuspended in HBSS at 1 x 107
cells/ml. The neutrophils were activated by
1 pM phorbol myristate acetate.
Interleukin-1-induced Modelof
PulmonaryInjury
Administration ofIL-1 to Intact Rats.
Rats were anesthetized with ketamine
(90 mg/kg) and xylazine (7 mg/kg) ip and
supplemented as needed with ketamine
(68 mg/kg) and xylazine (5 mg/kg).
Subsequently, the trachea was cannulated
with an indwelling 16-g stub adaptor tube.
After five ventilated breaths (Harvard
Apparatus Co., South Natick, MA), 0.5 ml
containing 50 ng IL-1 in sterile saline was
rapidly instilled intratracheally and then
followed by another five ventilated breaths.
Sham-treated rats received identical anes-
thesia and surgery but were injected with
sterile saline or heat-inactivated IL-1 intra-
tracheally. Control rats received no surgery
or treatment and were anesthetized only
immediately before sacrifice. Rats were kept
on a warming blanket, and temperatures
were monitored throughout the experiment.
Assessment ofLung Leak. Rats were
injected iv with 1.0 pC (0.5 ml) of 1251_
labeled bovine serum albumin 4.5 hr after
IL-1 administration. Rats were ventilated
25 min later with a Harvard small animal
respirator and then subjected to laparo-
tomy, thoracotomy, and then right ventric-
ular injection of heparin (200 U, 0.2 ml).
Subsequently, 30 min after 1251 injection,
blood samples were obtained, lungs were
perfused blood-free with phosphate-
buffered saline and excised. Right lungs
and blood samples were counted in a
gamma counter (Beckman, Fullerton, CA).
Lung leak index (lung leak) is defined as





Four groups of rats were treated as
described above, and lung leak was
quantified: group 1, sham-treated animals
(no IL-1); group 2, sham-treated animals
pretreated by iv injection of 2 mg
MnSOD; group 3, IL-1-treated animals;
and group 4, IL-1-treated animals pre-
treated by iv injection of 2 mg MnSOD.
The results are shown in Figure 1. The IL-
1-induced increase in lung leak was sup-
pressed by approximately 50% in the
MnSOD-treated animals. This group was
significantly different from both control
groups and from the untreated IL-1 group.
Elimination byTrypsinoftheAbility
ofECSOD to Bindto Heparin
Trypsin (5 lig in 0.5 pl of 1 mM HCl) was
added to 120 U ofrabbit ECSOD-C in 0.5
ml of HBSS and incubated for 1 hr at
37°C. The solution was then subjected to
heparin-agarose affinity chromatography as
described above. The results (Figure 2)
show that while the native ECSOD-C
binds to the heparin column and is eluted
at a salt concentration ofabout 0.4 M, the




Isolated human neutrophils from a healthy
donor were8resuspended at a concentration
of 1.4 x 10 cells/ml in HBSS containing
rabbit ECSOD-C (240 U/ml). The cells in
one aliquot (0.5 ml) were activated by the
addition of 1 pM phorbol myristate acetate.
The mixtures were then incubated for 1 hr
at 37°C and each was subjected to heparin-
agarose affinity chromatography. The
results (Figure 3) show that while resting
neutrophils did not affect the affinity ofthe
enzyme for heparin, incubation with acti-
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Figure 1. Mn-SOD significantly decreases lung leak in
rats administered IL-1 intratracheally. Differences
among groups are significant at p<0.05 where indi-
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Figure 2. Native rabbit ECSOD-C binds to the heparin
affinity column and is released when the sodium chlo-
ride gradient reaches about 0.4 M. Incubation with

















Figure 3. Incubation of rabbit ECSOD-C with resting
human neutrophils does not affect heparin affinity,
whereas incubation with neutrophils stimulated by
phorbol myristate acetate results in decreased binding
to heparin.
significantly. The major peak from this
incubation eluted at a NaCI concentration
ofabout 0.3 M, compared to 0.4 M for the
native ECSOD-C, and two smaller peaks
eluted at about 0.15 and 0 M salt.
SOD Content ofPlasma fromARDS
To determine whether the plasma concen-
trations of SODs are perturbed in ARDS
patients, we fractionated plasma from a
patient with ARDS and from a control by
gel exclusion chromatography on Sephacryl
S-200 (Pharmacia, Uppsala, Sweden).
Plasma samples (1.2 ml) were applied to a
column (1 x 50 cm) and eluted with 10
mM potassium phosphate, pH 7.4, con-





been standardized with samples ofpurified
rabbit ECSOD-C and human recombinant
Cu,Zn- and Mn-SODs. The elution
profiles (Figure 4) reveal only trace amounts
ofSOD activity in the healthy plasma, but
significant amounts of all three SODs in
the ARDS plasma. The appearance of the
soluble ECSOD-A peak suggests that degra-
dation ofECSOD-C is taking place in this
patient. The appearance ofthe intracellular
Cu,Zn- and Mn-SODs suggests that cell
lysis is also occurring in the patient.
Discussion
In terms ofprotecting the external surfaces
ofcells from attack by superoxide and sec-
ondarily derived species, ECSOD-C may
play avital role. The endothelium, which is
subjected to the oxidants produced by
adherent neutrophils during times of
inflammation, is especially vulnerable. It is
normally covered by a protective coating of
ECSOD-C, an enzyme that appears to be
specifically designed for this purpose. It
adheres tightly to the polyanionic heparan
sulfate on the endothelial surface by virtue
of the positively charged hydrophilic car-
boxy-terminal tail, rich in lysine and argi-
nine residues (16,21). When neutrophils
become activated as in ARDS, several
significant changes occur. The exposure of
the endothelium to superoxide goes up
dramatically as the adherent neutrophils
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Figure 4. Fractionation of sera from a normal individ-
ual and an ARDS patient on Sephacryl S-200 gel filtra-
tion medium. Only trace amounts of SOD activity are
present in the normal serum, but the ARDS serum
shows significant amounts of all three SODs, sepa-
rated here by their size differences. Purified rabbit
ECSOD-C elutes from this column in the bracketed
range indicated.
degranulate, a variety of proteolytic
enzymes is released. We have found that
activated neutrophils are capable ofcausing
partial proteolysis of ECSOD-C, resulting
in a diminished affinity for the endothelial
surface. These hypothetical changes are
illustrated in Figure 5.
Karlsson et al. (22) have also noted that
plasmin as well as trypsin can abolish the
heparin affinity of ECSOD-C. This vul-
nerability of ECSOD-C to proteolysis, we
believe, raises the possibility of its involve-
ment in a wide range of diseases that pro-
duce increased levels ofproteolytic activity
in the plasma (whether locally or systemi-
cally), as well as increased levels of oxida-
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Figure 5. While the normal endothelium is protected
by a coating of ECSOD-C, this coating may be stripped
away by the proteases (P) released from adherent acti-
vated neutrophils, leaving the endothelium vulnerable
to oxidative attack.
tive stress. The phenomenon also casts new
light on the therapeutic use of superoxide
dismutases. A relatively high concentration
of soluble SOD in the extracellular fluid
may not be able to provide the necessary
protection to the endothelium that could
be provided by a much smaller amount of
SOD if it were bound to the cell surfaces.
Note that in Figure 1 the exogenously
administered Mn-SOD provided
significant protection to the IL-1-treated
lung, but not maximal protection. This
might mean, of course, that the injury is
not totally superoxide-mediated, or it
might mean the effective concentration of
SOD at the endothelial surface was simply
inadequate.
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